Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Operating Leases (2019 - 2026)

Champions Oncology has reported Operating Leases over the past 8 years, most recently at $3.4 million for Q1 2026.

  • Quarterly results put Operating Leases at $3.4 million for Q1 2026, down 32.74% from a year ago — trailing twelve months through Jan 2026 was $3.4 million (down 32.74% YoY), and the annual figure for FY2025 was $4.6 million, down 23.95%.
  • Operating Leases for Q1 2026 was $3.4 million at Champions Oncology, down from $5.3 million in the prior quarter.
  • Over the last five years, Operating Leases for CSBR hit a ceiling of $9.0 million in Q4 2022 and a floor of $3.4 million in Q1 2026.
  • Median Operating Leases over the past 5 years was $7.1 million (2024), compared with a mean of $6.7 million.
  • Biggest five-year swings in Operating Leases: skyrocketed 48.64% in 2022 and later tumbled 40.28% in 2025.
  • Champions Oncology's Operating Leases stood at $9.0 million in 2022, then decreased by 10.21% to $8.0 million in 2023, then plummeted by 33.24% to $5.4 million in 2024, then fell by 1.95% to $5.3 million in 2025, then crashed by 36.14% to $3.4 million in 2026.
  • The last three reported values for Operating Leases were $3.4 million (Q1 2026), $5.3 million (Q4 2025), and $4.2 million (Q3 2025) per Business Quant data.